XYZAL ALLERGY 24HR (Levocetirizine Dihydrochloride) Patent Expiration, LOE Window & CMS Spending

XYZAL ALLERGY 24HR (Levocetirizine Dihydrochloride) by Sanofi: FDA Orange Book core substance LOE 2027-10-16, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSanofi
FDA Application & PathwayN209090 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-10-16
Last Listed Patent or Exclusivity Date2027-10-16
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.